DDInter557 DDInter1376
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
Dihydroergotamine {u} (Compound) palliates {v} (Disease) migraine
Dihydroergotamine {u} (Compound) is included by {v} (Pharmacologic Class) Ergotamines
Dihydroergotamine {u} (Compound) downregulates {v} (Gene) CTNND1
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Injury
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound)
Dihydroergotamine (Compound) binds ABCB1 (Gene)
Dihydroergotamine (Compound) palliates migraine (Disease)
Dihydroergotamine (Compound) is included by Ergotamines (Pharmacologic Class)
Dihydroergotamine (Compound) downregulates CTNND1 (Gene)
Dihydroergotamine (Compound) causes Injury (Side Effect)